ATE443259T1 - Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests - Google Patents

Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests

Info

Publication number
ATE443259T1
ATE443259T1 AT02761799T AT02761799T ATE443259T1 AT E443259 T1 ATE443259 T1 AT E443259T1 AT 02761799 T AT02761799 T AT 02761799T AT 02761799 T AT02761799 T AT 02761799T AT E443259 T1 ATE443259 T1 AT E443259T1
Authority
AT
Austria
Prior art keywords
circulative
antigens
antigen
determination
therapeutic antibodies
Prior art date
Application number
AT02761799T
Other languages
English (en)
Inventor
Maher Albitar
Michael Keating
Taghi Manshouri
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE443259T1 publication Critical patent/ATE443259T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT02761799T 2001-09-20 2002-09-20 Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests ATE443259T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32367901P 2001-09-20 2001-09-20
PCT/US2002/030142 WO2003024993A2 (en) 2001-09-20 2002-09-20 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays

Publications (1)

Publication Number Publication Date
ATE443259T1 true ATE443259T1 (de) 2009-10-15

Family

ID=23260258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02761799T ATE443259T1 (de) 2001-09-20 2002-09-20 Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests

Country Status (7)

Country Link
US (10) US7718387B2 (de)
EP (2) EP1438583B1 (de)
JP (4) JP4424987B2 (de)
AT (1) ATE443259T1 (de)
AU (1) AU2002327037A1 (de)
DE (1) DE60233744D1 (de)
WO (1) WO2003024993A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
CA2396793A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
US7718387B2 (en) * 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
CN1692127A (zh) * 2002-07-25 2005-11-02 健泰科生物技术公司 Taci抗体及其用途
EP3263596A1 (de) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulinvarianten und ihre verwendungen
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
BRPI0412217A (pt) * 2003-07-29 2006-08-22 Genentech Inc método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista
KR20060132554A (ko) * 2003-08-29 2006-12-21 제넨테크, 인크. 안과 질병의 항-ｃｄ２０ 치료
US20050069958A1 (en) * 2003-09-26 2005-03-31 Mills Rhonda A. Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
EP2441465B1 (de) * 2003-10-24 2014-01-15 Nora Therapeutics, Inc. Zusammensetzungen und Verfahren für eine gesunde Schwangerschaft
CA2543830A1 (en) * 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
KR20060109494A (ko) * 2003-12-19 2006-10-20 제넨테크, 인크. 자가면역 질환의 치료에 있어서 ｃｄ20의 검출
MXPA06006865A (es) * 2003-12-19 2006-08-23 Genentech Inc Deteccion de cd20 en rechazo de transplante.
JP2007536246A (ja) * 2004-05-05 2007-12-13 ジェネンテック・インコーポレーテッド 自己免疫疾患の予防法
EP1765400A2 (de) * 2004-06-04 2007-03-28 Genentech, Inc. Verfahren zur behandlung von lupus
TW201422238A (zh) * 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
CN101027100A (zh) * 2004-07-22 2007-08-29 健泰科生物技术公司 治疗干燥综合征的方法
US20060024744A1 (en) * 2004-07-28 2006-02-02 Mills Rhonda A Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
CA2580271A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
EP1645284A1 (de) * 2004-10-08 2006-04-12 Charité - Universitätsmedizin Berlin Verwendung von CDw52-Liganden zur Behandlung von Erkrankungen, die auf degenerierten Makrophagen basieren
AU2005318407B2 (en) * 2004-12-23 2009-11-05 F. Hoffmann-La Roche Ag Detection of a therapeutic antibody in an experimental animal
ZA200705459B (en) * 2005-01-13 2008-09-25 Genentech Inc Treatment method
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ATE460672T1 (de) * 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
MY157955A (en) * 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
US20070042443A1 (en) * 2005-08-17 2007-02-22 Quest Diagnostics Investments Incorporated Hematopoietic cell phenotyping using free circulating cellular markers
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
DE102006012613B4 (de) * 2006-03-17 2010-01-14 Mpb Meltec Patent- Und Beteiligungsgesellschaft Mbh Verfahren zur Bestimmung der therapeutischen Wirksamkeit von Substanzen
EP2032719A2 (de) * 2006-06-02 2009-03-11 GlaxoSmithKline Biologicals S.A. Verfahren zur identifizierung des ansprechens bzw. nichtansprechens eines patienten auf eine immuntherapie
CA2662416C (en) 2006-09-12 2014-12-16 F. Hoffmann-La Roche Ag Anti-drug antibody assay
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2200631A1 (de) 2007-10-16 2010-06-30 Zymogenetics, Inc. Kombination aus blys-hemmung und anti-cd20-wirkstoffen zur behandlung von autoimmunerkrankungen
US20110311448A1 (en) * 2007-11-02 2011-12-22 Ann Marie Schmidt Antibody to rage and uses for in vivo imaging or for targeting therapy
US20100323457A1 (en) 2007-12-03 2010-12-23 Tokyo Institute Of Technology Biosensing method using coated magnetic fine particles and biosensing apparatus for biosensing method
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
US11051733B2 (en) * 2008-01-18 2021-07-06 Wake Forest University Health Sciences Isolating and purifying cells for therapy
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
MX358013B (es) 2009-11-13 2018-08-01 Amgen Inc Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
US8426151B2 (en) * 2010-02-10 2013-04-23 Companion Diagnostics Inc. Systems and methods for the detection of biomarkers
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
CN103068852B (zh) 2010-08-17 2016-04-20 弗·哈夫曼-拉罗切有限公司 抗人IgG1抗体
JP2014517294A (ja) * 2011-05-19 2014-07-17 バクスター・インターナショナル・インコーポレイテッド 循環ａｄａｍｔｓ１３抗体複合体の検出
US20140315742A1 (en) 2011-09-29 2014-10-23 Meso Scale Technologies, Llc Biodosimetry panels and methods
EP2750690B1 (de) 2011-11-15 2018-11-07 The Walter and Eliza Hall Institute of Medical Research Löslicher mediator
EP2676966A1 (de) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 als biochemisches Serum und Gewebemarker
MX346146B (es) 2012-07-13 2017-03-09 Hoffmann La Roche Metodo para detectar un aglutinante multiespecifico.
CA2878814C (en) 2012-08-17 2023-03-14 Morphosys Ag Complex-specific antibodies and antibody fragments and its use
AU2013344807B2 (en) * 2012-11-15 2018-05-24 The Walter And Eliza Hall Institute Of Medical Research Soluble mediator
US20150293086A1 (en) * 2014-04-14 2015-10-15 Abreos Biosciences, Inc. Lateral flow immunoassay
CN104360057B (zh) * 2014-10-22 2016-10-05 上海泰因生物技术有限公司 一种检测抗cd52抗体的elisa反应体系与方法
JP6407694B2 (ja) * 2014-12-16 2018-10-17 株式会社日立ハイテクノロジーズ プラズマ処理装置
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
EP4060344A1 (de) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Verfahren und kits
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
CN104965076B (zh) * 2015-07-14 2017-01-18 上海拜豪生物科技有限公司 一种镉螯合型免疫复合物及其制备方法和应用
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AU2016344665C1 (en) 2015-10-29 2023-07-27 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
USD800912S1 (en) 2016-06-17 2017-10-24 Abreos Biosciences, Inc. Point-of-care diagnostic device
EP3497444A4 (de) 2016-08-12 2020-11-11 Abreos Biosciences, Inc. Nachweis und quantifizierung von natalizumab
WO2019067526A1 (en) 2017-09-26 2019-04-04 Poet Research, Inc. SYSTEMS AND METHODS FOR TREATING LIGNOCELLULOSIC BIOMASS
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
EP4326437A4 (de) * 2021-04-21 2024-09-11 Siemens Healthcare Diagnostics, Inc. Zusammensetzungen, kits und verfahren für antimikrobielle serologietests unter verwendung von anti-humanem immunglobulinantikörper
CN115902235A (zh) * 2021-09-30 2023-04-04 长沙都正医学检验有限责任公司 利妥昔生物类似药双抗夹心elisa定量试剂盒及其应用
WO2023081898A1 (en) * 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5059522A (en) 1988-08-18 1991-10-22 Wayne Lawrence G Intrinsic enzyme dot blot immunoassay or indentification of microorganisms
US5227159A (en) 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
WO1991006866A2 (en) 1989-11-03 1991-05-16 Morton Donald L Urinary tumor associated antigen, antigenic subunits uses and methods of detection
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5726064A (en) 1990-11-22 1998-03-10 Applied Research Systems Ars Holding Nv Method of assay having calibration within the assay
US5234816A (en) 1991-07-12 1993-08-10 Becton, Dickinson And Company Method for the classification and monitoring of leukemias
US5525461A (en) * 1991-11-01 1996-06-11 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using total leukocyte surface antigens
US5597735A (en) 1992-05-11 1997-01-28 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health And Welfare Glycolipids for serodiagnosis of tuberculosis and leprosy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5667981A (en) 1994-05-13 1997-09-16 Childrens Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
JP4763135B2 (ja) * 1998-12-23 2011-08-31 メザイク プロプライエトリー リミティッド 結合相手を検出するための検定法
US7718387B2 (en) 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays

Also Published As

Publication number Publication date
DE60233744D1 (de) 2009-10-29
EP1438583B1 (de) 2009-09-16
US20160069902A1 (en) 2016-03-10
EP1438583A4 (de) 2006-05-17
EP2131198B1 (de) 2013-03-27
US20110236994A1 (en) 2011-09-29
US20130004977A1 (en) 2013-01-03
US20180045736A1 (en) 2018-02-15
US8232068B2 (en) 2012-07-31
US20030068664A1 (en) 2003-04-10
JP2012198232A (ja) 2012-10-18
EP1438583A2 (de) 2004-07-21
AU2002327037A1 (en) 2003-04-01
US20140335549A1 (en) 2014-11-13
US7943332B2 (en) 2011-05-17
JP2005533236A (ja) 2005-11-04
US9157916B2 (en) 2015-10-13
US8501423B2 (en) 2013-08-06
HK1068411A1 (en) 2005-04-29
EP2131198A3 (de) 2010-07-07
US20120107846A1 (en) 2012-05-03
JP5264522B2 (ja) 2013-08-14
US20100221761A1 (en) 2010-09-02
JP5781014B2 (ja) 2015-09-16
US8114618B2 (en) 2012-02-14
WO2003024993A2 (en) 2003-03-27
JP2014089213A (ja) 2014-05-15
US20140011215A1 (en) 2014-01-09
JP4424987B2 (ja) 2010-03-03
US10018638B2 (en) 2018-07-10
EP2131198A2 (de) 2009-12-09
JP2009075139A (ja) 2009-04-09
US20190041399A1 (en) 2019-02-07
WO2003024993A3 (en) 2003-10-16
US7718387B2 (en) 2010-05-18
US8790882B2 (en) 2014-07-29

Similar Documents

Publication Publication Date Title
ATE443259T1 (de) Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
Ahn et al. Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood
EA200500643A1 (ru) Способ неконкурентного иммуноанализа для определения малых аналитов
DK1139101T3 (da) Immunobestemmelse for C-reaktivt protein
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
EP1585966A4 (de) VERFAHREN ZUR IDENTIFIZIERUNG VON AUF DIE BEHANDLUNG MIT ANTI-ErbB2-ANTIK RPERN REAGIERENDEN TUMOREN
FI20030652A0 (fi) Parannettu immunomääritys
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
RU2001132335A (ru) Способ оценки наличия риска пептической язвы, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и гастрин-17 в образце сыворотки
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
Grebenchtchikov et al. An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood
ATE519108T1 (de) Detektion von analyten in fäkalproben
ATE78601T1 (de) Test fuer menschlichen brustkrebs.
Medawar et al. Fluorescent immunosensor using AP-SNs and QDs for quantitation of IgG anti-Toxocara canis
EP1245957A3 (de) Methode zur Konzentrationsbestimmung von Ceruloplasmin in einem Blutflecken mittels enzymgekoppeltem Immunosorbent-Assay oder mittels dissoziationsverstärktem, zeitaufgelöstem Immunofluoreszenzassay, sowie Kit zum Auffinden der Wilson-Krankheit und Diagnosemethode für letztere
CN101088010B (zh) 用于测定抗原的试剂以及抗原的测定方法
WO2001075449A1 (fr) Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
EP1308730A4 (de) Verfahren zum nachweis oder zum bestimmen von hbv
ATE481644T1 (de) Prognose des verlaufs einer krebserkrankung
DK0991945T4 (da) Fremgangsmåde til identifikation af tumor-antigener med autoantistoffer i serum
WO2003101176A3 (en) Method, composition and kit for antigenic binding of norwalk-like viruses
JP2009517667A (ja) サンプル中の被検体（抗原）および該被検体を標的とする治療用抗体を同時に免疫化学的に測定するためのイムノアッセイ（リカバリー・イムノアッセイ（ＲｅｃｏｖｅｒｙＩｍｍｕｎｏａｓｓａｙ））
NO20052870D0 (no) Immunoanalysemetode og sett for anvendelse derav
Kemeny et al. Improved sensitivity and specificity of sandwich, competitive and capture enzyme-linked immunosorbent assays for allergen-specific antibodies
ATE408830T1 (de) Verfahren und antikörper zum nachweis von alkoholkonsum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties